Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 1
2013 2
2014 1
2015 1
2016 2
2017 2
2018 2
2019 5
2020 2
2021 6
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for stefano braf
Your search for Stefano Brafa retrieved no results
Integrated proteogenomic characterization of glioblastoma evolution.
Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, Kwon HJ, Ha S, Garofano L, Oh YT, D'Angelo F, Kim CI, Kim S, Lee JY, Kim J, Hong J, Jang EH, Mathon B, Di Stefano AL, Bielle F, Laurenge A, Nesvizhskii AI, Hur EM, Yin J, Shi B, Kim Y, Moon KS, Kwon JT, Lee SH, Lee SH, Gwak HS, Lasorella A, Yoo H, Sanson M, Sa JK, Park CK, Nam DH, Iavarone A, Park JB. Kim KH, et al. Cancer Cell. 2024 Mar 11;42(3):358-377.e8. doi: 10.1016/j.ccell.2023.12.015. Epub 2024 Jan 11. Cancer Cell. 2024. PMID: 38215747
Inhibition of B-raf proto-oncogene (BRAF) kinase impairs both neuronal transition and migration capability of recurrent tumor cells, phenotypic hallmarks of post-therapy progression. Combinatorial treatment of temozolomide (TMZ) with BRAF inhibitor, vemurafenib, sig …
Inhibition of B-raf proto-oncogene (BRAF) kinase impairs both neuronal transition and migration capability of recurrent tumor cells, …
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.
Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, Gelsomino F. Caputo F, et al. Int J Mol Sci. 2019 Oct 28;20(21):5369. doi: 10.3390/ijms20215369. Int J Mol Sci. 2019. PMID: 31661924 Free PMC article. Review.
Chemotherapy plus bevacizumab is the current standard therapy in first-line treatment of BRAF-mutated metastatic CRC (mCRC), with triplet (FOLFOXIRI) plus bevacizumab as a valid option in patients with a good performance status. BRAF inhibitors are not so effective …
Chemotherapy plus bevacizumab is the current standard therapy in first-line treatment of BRAF-mutated metastatic CRC (mCRC), with tri …
The evolving role of microsatellite instability in colorectal cancer: A review.
Gelsomino F, Barbolini M, Spallanzani A, Pugliese G, Cascinu S. Gelsomino F, et al. Cancer Treat Rev. 2016 Dec;51:19-26. doi: 10.1016/j.ctrv.2016.10.005. Epub 2016 Oct 27. Cancer Treat Rev. 2016. PMID: 27838401 Free article. Review.
MSI-H colorectal cancers have distinct clinical and pathological features such as proximal location, early-stage (predominantly stage II), poor differentiation, mucinous histology and association with BRAF mutations. In early-stage CRC, MSI can select a group of tumors wit …
MSI-H colorectal cancers have distinct clinical and pathological features such as proximal location, early-stage (predominantly stage II), p …
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S, De Falco V, Martini G, Ciardiello D, Martinelli E, Della Corte CM, Esposito L, Famiglietti V, Di Liello A, Avallone A, Cardone C, De Stefano A, Montesarchio V, Zampino MG, Bordonaro R, Scartozzi M, Santini D, Di Maio M, De Vita F, Altucci L, Marrone F, Ciardiello F, Troiani T. Napolitano S, et al. JAMA Oncol. 2023 Jul 1;9(7):966-970. doi: 10.1001/jamaoncol.2023.0655. JAMA Oncol. 2023. PMID: 37200022 Free PMC article. Clinical Trial.
Median PFS was 4.0 months (95% CI, 2.8-5.3 months) in the panitumumab plus trifluridine-tipiracil arm vs 2.5 months (95% CI, 1.4-3.6 months) in the trifluridine-tipiracil only (hazard ratio [HR], 0.48; 95% CI, 0.28-0.82; P = .007). Pretreatment plasma RAS/BRAF WT ctDNA ide …
Median PFS was 4.0 months (95% CI, 2.8-5.3 months) in the panitumumab plus trifluridine-tipiracil arm vs 2.5 months (95% CI, 1.4-3.6 months) …
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antoniotti C, Ambrosini M, Piva VM, Nichetti F, Fassan M, Cremolini C, Lonardi S. Pietrantonio F, et al. Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20. Eur J Cancer. 2023. PMID: 37924647 Free article.
BACKGROUND: Upfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type mCRC. Molecular 'hyperselection' may optimize EGFR inhibition by detecting additional resistance alterations. ...CONCLUSIONS: Molecular hype …
BACKGROUND: Upfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type …
Innovating Strategies and Tailored Approaches in Neuro-Oncology.
Picca A, Guyon D, Santonocito OS, Baldini C, Idbaih A, Carpentier A, Naccarato AG, Caccese M, Lombardi G, Di Stefano AL. Picca A, et al. Cancers (Basel). 2022 Feb 22;14(5):1124. doi: 10.3390/cancers14051124. Cancers (Basel). 2022. PMID: 35267432 Free PMC article. Review.
Nonetheless, advances in molecular biology allowed to identify several druggable alterations in a subset of IDH wild-type gliomas, such as NTRK and FGFR-TACC fusions, and BRAF hotspot mutations. Multi-tyrosine kinase inhibitors, such as regorafenib, also showed efficacy in …
Nonetheless, advances in molecular biology allowed to identify several druggable alterations in a subset of IDH wild-type gliomas, such as N …
The role of microRNAs in thyroid carcinomas.
Forte S, La Rosa C, Pecce V, Rosignolo F, Memeo L. Forte S, et al. Anticancer Res. 2015 Apr;35(4):2037-47. Anticancer Res. 2015. PMID: 25862858 Review.
While TC causes are not completely understood, many genetic factors involved in their onset have been discovered. In particular, activating mutations of BRAF, RET or RAS genes are known to be specifically associated with TC initiation, progression and outcome. ...
While TC causes are not completely understood, many genetic factors involved in their onset have been discovered. In particular, activating …
Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors.
Lazzarini E, Silvestris DA, Benvenuto G, Osti D, Fattore L, Paterra R, Finocchiaro G, Malatesta P, Daga A, Gallotti AL, Galli R, Pelicci G, Tesei A, Bedeschi M, Pallini R, Pasqualini L, Romualdi C, Gallo A, Ricci-Vitiani L, Indraccolo S. Lazzarini E, et al. J Neurooncol. 2023 May;163(1):47-59. doi: 10.1007/s11060-023-04287-6. Epub 2023 May 4. J Neurooncol. 2023. PMID: 37140883 Free PMC article.
RESULTS: Exome sequencing revealed TP53 as the main mutated gene (41/94 samples, 44%), followed by PTEN (33/94, 35%), RB1 (16/94, 17%) and NF1 (15/94, 16%), among other genes associated to brain tumors. One GSC sample bearing a BRAF p.V600E mutation showed sensitivity in v …
RESULTS: Exome sequencing revealed TP53 as the main mutated gene (41/94 samples, 44%), followed by PTEN (33/94, 35%), RB1 (16/94, 17%) and N …
Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma.
Di Stefano AL, Guyon D, Sejean K, Feuvret L, Villa C, Berzero G, Desforges Bullet V, Halimi E, Boulin A, Baussart B, Gaillard S. Di Stefano AL, et al. Neurooncol Adv. 2020 Oct 15;2(1):vdaa141. doi: 10.1093/noajnl/vdaa141. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33241217 Free PMC article. No abstract available.
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study).
Calegari MA, Salvatore L, Di Stefano B, Basso M, Orlandi A, Boccaccino A, Lombardo F, Auriemma A, Zurlo IV, Bensi M, Camarda F, Ribelli M, Vivolo R, Cocomazzi A, Pozzo C, Milella M, Martini M, Bria E, Tortora G. Calegari MA, et al. Cancers (Basel). 2021 Apr 27;13(9):2098. doi: 10.3390/cancers13092098. Cancers (Basel). 2021. PMID: 33925278 Free PMC article.
This study aimed to confirm features and prognosis of rare BRAF non-V600 mCRCs compared to BRAF V600E and BRAF wild-type mCRCs treated at two Italian Institutions. Overall, 537 cases were retrospectively evaluated: 221 RAS/BRAF wild-type, 261 RAS mutat …
This study aimed to confirm features and prognosis of rare BRAF non-V600 mCRCs compared to BRAF V600E and BRAF wild-typ …
36 results